» Authors » Duncan Brown

Duncan Brown

Explore the profile of Duncan Brown including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 316
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yule M, Machado A, Brown L, Rocha B, Patton R, Sayers J, et al.
Clin Nutr ESPEN . 2025 Mar; PMID: 40086693
Background & Aims: The Global Leadership Initiative on Malnutrition (GLIM) criteria have been recommended for the diagnosis of malnutrition. It requires that the patient meets at least one phenotypic criterion...
2.
Yarlas A, Lovley A, Brown D, Vera-Llonch M, Khella S, Karam C
BMC Neurol . 2023 Mar; 23(1):108. PMID: 36932361
Background: Patients with hereditary transthyretin amyloidosis (ATTRv) frequently experience symptoms of polyneuropathy (PN) that worsen over time and impair daily functioning. Previous analyses supported efficacy of inotersen, an antisense oligonucleotide,...
3.
Wadsworth B, Kruger P, Hukins C, Modderman G, Brown D, Paratz J
Spinal Cord . 2023 Mar; 61(6):330-337. PMID: 36932257
Study Design: A prospective cohort of patients with acute tetraplegia. Objectives: This study aimed to determine the feasibility of using mouthpiece ventilation (MPV) in the intensive care unit (ICU) for...
4.
ONeill K, Powell M, Lovell T, Brown D, Walsham J, Calleja P, et al.
Aust Crit Care . 2023 Jan; 36(5):799-805. PMID: 36621344
Background: Patient handover continues to be an international health priority in the prevention of patient harm. Transitioning patients from the intensive care unit (ICU) to the ward is complex, particularly...
5.
Nativi-Nicolau J, Fine N, Ortiz-Perez J, Brown D, Vera-Llonch M, Reddy S, et al.
J Comp Eff Res . 2022 Aug; 11(14):1031-1044. PMID: 35993313
Initial clinical manifestations of transthyretin amyloidosis (ATTR) are not well understood, making timely diagnosis challenging. Patients aged ≥68 years newly diagnosed with ATTR were identified using Medicare Research Identifiable Files....
6.
Williams L, Gerber D, Elder A, Tseng W, Baru V, Delaney-Busch N, et al.
Mol Ther Nucleic Acids . 2022 Jul; 29:189-203. PMID: 35860385
Mutations in the gene are the cause of an ultra-rare neurological disorder characterized by intellectual disability, impaired speech, motor delay, and hypotonia evolving to spasticity, central sleep apnea, and premature...
7.
Karam C, Brown D, Yang M, Done N, Zhu J, Greatsinger A, et al.
Muscle Nerve . 2022 Jul; 66(4):438-446. PMID: 35799473
Introduction/aims: Hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN) progressively affects patients' functionality and compromises health-related quality of life (HRQL). The aim of this study was to quantify the projected long-term treatment...
8.
Karam C, Brown D, Yang M, Done N, Dieye I, Bozas A, et al.
Muscle Nerve . 2022 Jun; 66(3):319-328. PMID: 35766224
Introduction/aims: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a genetic condition associated with significant morbidity and mortality. In this study we aimed to identify patient subgroups exhibiting the greatest health-related...
9.
Patton R, Cook J, Haraldsdottir E, Brown D, Dolan R, McMillan D, et al.
PLoS One . 2021 Dec; 16(12):e0261175. PMID: 34914733
Introduction: There is a pressing need for a holistic characterisation of people with incurable cancer. In this group, where quality of life and improvement of symptoms are therapeutic priorities, the...
10.
Hall C, Skipworth R, Blackwood H, Brown D, Cook J, Diernberger K, et al.
J Cachexia Sarcopenia Muscle . 2021 Oct; 12(6):2034-2044. PMID: 34612012
Background: Despite rehabilitation being increasingly advocated for people living with incurable cancer, there is limited evidence supporting efficacy or component parts. The progressive decline in function and nutritional in this...